Legal & General Group PLC Acadia Pharmaceuticals Inc Transaction History

Legal & General Group PLC

  • $470 Billion
  • Q3 2024

A detailed history of Legal & General Group PLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Legal & General Group PLC holds 135,390 shares of ACAD stock, worth $2.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
135,390
Previous 135,390 -0.0%
Holding current value
$2.35 Million
Previous $2.08 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$15.14 - $19.14 $40,635 - $51,371
2,684 Added 2.02%
135,390 $2.08 Million
Q2 2024

Aug 14, 2024
BUY
$14.62 - $18.42 $163,159 - $205,567
11,160 Added 9.18%
132,706 $2.16 Million
Q1 2024

Jul 01, 2024
BUY
$17.79 - $30.86 $163,685 - $283,942
9,201 Added 8.19%
121,546 $2.25 Million
Q1 2024

May 14, 2024
SELL
$17.79 - $30.86 $62,318 - $108,102
-3,503 Reduced 3.02%
112,345 $2.08 Million
Q4 2023

Feb 15, 2024
BUY
$20.78 - $31.77 $7,356 - $11,246
354 Added 0.31%
115,848 $3.63 Million
Q3 2023

Nov 14, 2023
BUY
$20.84 - $33.47 $11,962 - $19,211
574 Added 0.5%
115,494 $2.41 Million
Q2 2023

Aug 14, 2023
SELL
$17.8 - $25.65 $39,373 - $56,737
-2,212 Reduced 1.89%
114,920 $2.75 Million
Q1 2023

May 15, 2023
BUY
$16.32 - $20.92 $101,102 - $129,599
6,195 Added 5.58%
117,132 $2.2 Million
Q4 2022

Feb 14, 2023
SELL
$14.2 - $18.63 $10,153 - $13,320
-715 Reduced 0.64%
110,937 $1.77 Million
Q3 2022

Nov 14, 2022
SELL
$14.11 - $18.27 $78,282 - $101,361
-5,548 Reduced 4.73%
111,652 $1.83 Million
Q2 2022

Aug 22, 2022
SELL
$13.01 - $27.22 $32,511 - $68,022
-2,499 Reduced 2.09%
117,200 $1.65 Million
Q1 2022

May 16, 2022
BUY
$20.94 - $27.5 $336,819 - $442,337
16,085 Added 15.52%
119,699 $2.9 Million
Q4 2021

Feb 14, 2022
SELL
$16.79 - $27.09 $61,182 - $98,715
-3,644 Reduced 3.4%
103,614 $2.42 Million
Q3 2021

Nov 15, 2021
BUY
$15.78 - $24.77 $388,361 - $609,614
24,611 Added 29.78%
107,258 $1.78 Million
Q2 2021

Aug 12, 2021
SELL
$19.4 - $27.42 $959,388 - $1.36 Million
-49,453 Reduced 37.44%
82,647 $2.02 Million
Q1 2021

May 17, 2021
SELL
$25.02 - $54.99 $35,253 - $77,480
-1,409 Reduced 1.06%
132,100 $3.41 Million
Q4 2020

Feb 12, 2021
SELL
$41.04 - $56.79 $541,563 - $749,400
-13,196 Reduced 8.99%
133,509 $7.14 Million
Q3 2020

Nov 13, 2020
SELL
$36.42 - $57.0 $14,130 - $22,116
-388 Reduced 0.26%
146,705 $6.05 Million
Q2 2020

Aug 14, 2020
BUY
$39.26 - $52.73 $2.71 Million - $3.64 Million
68,995 Added 88.34%
147,093 $7.13 Million
Q1 2020

May 14, 2020
BUY
$31.65 - $46.87 $184,203 - $272,783
5,820 Added 8.05%
78,098 $3.3 Million
Q4 2019

Feb 13, 2020
BUY
$36.21 - $51.4 $445,201 - $631,963
12,295 Added 20.5%
72,278 $3.09 Million
Q3 2019

Nov 13, 2019
BUY
$22.22 - $44.01 $144,696 - $286,593
6,512 Added 12.18%
59,983 $2.16 Million
Q2 2019

Aug 14, 2019
SELL
$23.32 - $28.12 $16,324 - $19,684
-700 Reduced 1.29%
53,471 $1.43 Million
Q1 2019

May 15, 2019
BUY
$16.17 - $27.38 $194,428 - $329,217
12,024 Added 28.53%
54,171 $1.46 Million
Q4 2018

Feb 15, 2019
BUY
$14.32 - $22.92 $112,841 - $180,609
7,880 Added 23.0%
42,147 $681,000
Q2 2018

Aug 10, 2018
SELL
$15.07 - $22.34 $213,345 - $316,267
-14,157 Reduced 29.24%
34,267 $523,000
Q1 2018

May 17, 2018
SELL
$22.47 - $32.33 $43,030 - $61,911
-1,915 Reduced 3.8%
48,424 $1.09 Million
Q4 2017

Feb 13, 2018
BUY
$26.84 - $39.14 $1.35 Million - $1.97 Million
50,339
50,339 $1.52 Million

Others Institutions Holding ACAD

# of Institutions
279
Shares Held
156M
Call Options Held
901K
Put Options Held
314K
View Full List

About ACADIA PHARMACEUTICALS INC

ACAD Quotes by TradingView
  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.81B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email